125 related articles for article (PubMed ID: 30688385)
1. Prospective evaluation of pretreatment and intratreatment FDG PET-CT SUV stability in primary head and neck cancer.
Mendez LC; Conrad T; Lee J; Smith B; Brotherston D; Le T; Kiss A; Caldwell CB; Karam I; Poon I
Head Neck; 2019 Jun; 41(6):1889-1894. PubMed ID: 30688385
[TBL] [Abstract][Full Text] [Related]
2. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
[TBL] [Abstract][Full Text] [Related]
3. Using FDG-PET to measure early treatment response in head and neck squamous cell carcinoma: quantifying intrinsic variability in order to understand treatment-induced change.
Hoang JK; Das SK; Choudhury KR; Yoo DS; Brizel DM
AJNR Am J Neuroradiol; 2013 Jul; 34(7):1428-33. PubMed ID: 23391836
[TBL] [Abstract][Full Text] [Related]
4. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
[TBL] [Abstract][Full Text] [Related]
5. Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study.
Schinagl DA; Span PN; Oyen WJ; Kaanders JH
Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1449-58. PubMed ID: 21461734
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
[TBL] [Abstract][Full Text] [Related]
7. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value.
Higgins KA; Hoang JK; Roach MC; Chino J; Yoo DS; Turkington TG; Brizel DM
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):548-53. PubMed ID: 21277108
[TBL] [Abstract][Full Text] [Related]
8. Adaptive 18fluoro-2-deoxyglucose positron emission tomography/computed tomography-based target volume delineation in radiotherapy planning of head and neck cancer.
Moule RN; Kayani I; Prior T; Lemon C; Goodchild K; Sanghera B; Wong WL; Saunders MI
Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):364-71. PubMed ID: 21109410
[TBL] [Abstract][Full Text] [Related]
9. Adherence to pretreatment and intratreatment imaging of head and neck squamous cell carcinoma patients undergoing (chemo) radiotherapy in a research setting.
Martens RM; Koopman T; Noij DP; de Bree R; Vergeer MR; Zwezerijnen G; Leemans CR; de Graaf P; Boellaard R; Castelijns JA
Clin Imaging; 2021 Jan; 69():82-90. PubMed ID: 32693228
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer.
Machtay M; Natwa M; Andrel J; Hyslop T; Anne PR; Lavarino J; Intenzo CM; Keane W
Head Neck; 2009 Feb; 31(2):195-201. PubMed ID: 19107945
[TBL] [Abstract][Full Text] [Related]
11. Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions.
Mohamed ASR; Cardenas CE; Garden AS; Awan MJ; Rock CD; Westergaard SA; Brandon Gunn G; Belal AM; El-Gowily AG; Lai SY; Rosenthal DI; Fuller CD; Aristophanous M
Radiother Oncol; 2017 Aug; 124(2):248-255. PubMed ID: 28774596
[TBL] [Abstract][Full Text] [Related]
12. Tumor to cervical spinal cord standardized uptake ratio (SUR) improves the reproducibility of
van den Bosch S; Dijkema T; Philippens MEP; Terhaard CHJ; Hoebers FJP; Kaanders JHAM; Oyen WJG
Radiother Oncol; 2019 Jan; 130():39-45. PubMed ID: 30005954
[TBL] [Abstract][Full Text] [Related]
13. Use of 18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma.
Imsande HM; Davison JM; Truong MT; Devaiah AK; Mercier GA; Ozonoff AJ; Subramaniam RM
AJR Am J Roentgenol; 2011 Oct; 197(4):976-80. PubMed ID: 21940588
[TBL] [Abstract][Full Text] [Related]
14. Interaction of quantitative (18)F-FDG-PET-CT imaging parameters and human papillomavirus status in oropharyngeal squamous cell carcinoma.
Schouten CS; Hakim S; Boellaard R; Bloemena E; Doornaert PA; Witte BI; Braakhuis BJ; Brakenhoff RH; Leemans CR; Hoekstra OS; de Bree R
Head Neck; 2016 Apr; 38(4):529-35. PubMed ID: 25352335
[TBL] [Abstract][Full Text] [Related]
15. Preliminary assessment of dynamic contrast-enhanced CT implementation in pretreatment FDG-PET/CT for outcome prediction in head and neck tumors.
Abramyuk A; Wolf G; Shakirin G; Haberland U; Tokalov S; Koch A; Appold S; Zöphel K; Abolmaali N
Acta Radiol; 2010 Sep; 51(7):793-9. PubMed ID: 20583948
[TBL] [Abstract][Full Text] [Related]
16. Is image registration of fluorodeoxyglucose-positron emission tomography/computed tomography for head-and-neck cancer treatment planning necessary?
Fried D; Lawrence M; Khandani AH; Rosenman J; Cullip T; Chera BS
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):748-54. PubMed ID: 22414285
[TBL] [Abstract][Full Text] [Related]
17. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
[TBL] [Abstract][Full Text] [Related]
18. The role of changes in maximum standardized uptake value of FDG PET-CT for post-treatment surveillance in patients with head and neck squamous cell carcinoma treated with chemoradiotherapy: preliminary findings.
Matoba M; Tuji H; Shimode Y; Kondo T; Oota K; Tonami H
Br J Radiol; 2017 Mar; 90(1071):20150404. PubMed ID: 28055245
[TBL] [Abstract][Full Text] [Related]
19. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of
Chaput A; Robin P; Podeur F; Ollivier M; Keromnes N; Tissot V; Nonent M; Salaün PY; Rousset J; Abgral R
Laryngoscope; 2018 Feb; 128(2):378-385. PubMed ID: 28600822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
